Asociación de características de textura de la PET/TC con [18F]FDG con las características inmunohistoquímicas en el cáncer de mama ductal infiltrante

Önner, Hasan; Coşkun, Nazım; Erol, Mustafa; Karanis, Meryem İlkay Eren

doi:10.1016/j.remn.2020.10.009

Cited by 3 publications

(1 citation statement)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…La primera característica radiómica identificada en nuestro estudio fue la Matriz De Longitud De Secuencia De Nivel Gris (GL-RLM-SRHGE) con la mayor importancia relativa del modelo (1.0). Esta característica en su contraparte SRLGE (0.984), junto con otras caracterìsticas como GLZLM, GLCM y la entropía del histograma mostraron una correlación fuerte (r > 0.95) con SUVmax en el estudio realizado por Ömner et al 27 . En este estudio solo encontraron asociación con la característica GLZLM-SZLGE y metástasis (Log OR: 20.4, 95% CI 4.23-36.62 p = 0.013).…”

Section: Discussionunclassified

Predictores radiómicos F18-FDG PET/CT en la respuesta patológica completa a la quimioterapia neoadyuvante en pacientes con cáncer de mama

Lanzarin-Minero¹,

Reyes-Gonzalez²,

Fajardo-Fregoso³

2022

ARM

View full text Add to dashboard Cite

El objetivo del estudio fue evaluar el rendimiento diagnóstico de los predictores radiómicos F18-FDG PET/CT en la respuesta patológica completa a la quimioterapia neoadyuvante en pacientes con cáncer de mama. Material y métodos: Se utilizaron 127 registros para la conformación de un simulacro de datos y 19 fueron incluidos en el análisis final. Se analizó edad, respuesta al tratamiento y las características radiómicas. Resultados: La distribución de la respuesta al tratamiento fue parcial en 13 pacientes (68.42%), respuesta total en tres pacientes (15.79%), estabilidad en dos pacientes (19.53%) y progresión en una paciente (5.26%). Se construyó un conjunto empaquetado de un modelo LightGBM en 3 pliegues dadas 85 características originales. Conclusión: Se demostró un rendimiento diagnóstico de las características radiómicas superior al estándar de oro. Aunque aún hay que demostrar la utilidad de este enfoque en la predicción correcta y temprana del tratamiento, este estudio sugiere que las características radiómicas de textura obtenidas por PET/CT pueden ser útiles en la predicción de la respuesta al tratamiento.

show abstract

Section: Discussionunclassified

Predictores radiómicos F18-FDG PET/CT en la respuesta patológica completa a la quimioterapia neoadyuvante en pacientes con cáncer de mama

Lanzarin-Minero¹,

Reyes-Gonzalez²,

Fajardo-Fregoso³

2022

ARM

View full text Add to dashboard Cite

show abstract

The influence of receptor expression and clinical subtypes on baseline [18F]FDG uptake in breast cancer: systematic review and meta-analysis

et al. 2023

View full text Add to dashboard Cite

Background To quantify the relationship between [18F]FDG uptake of the primary tumour measured by PET-imaging with immunohistochemical (IHC) expression of ER, PR, HER2, Ki-67, and clinical subtypes based on these markers in breast cancer patients. Methods PubMed and Embase were searched for studies that compared SUVmax between breast cancer patients negative and positive for IHC expression of ER, PR, HER2, Ki-67, and clinical subtypes based on these markers. Two reviewers independently screened the studies and extracted the data. Standardized mean differences (SMD) and 95% confidence intervals (CIs) were estimated by using DerSimonian-Laird random-effects models. P values less than or equal to 5% indicated statistically significant results. Results Fifty studies were included in the final analysis. SUVmax is significantly higher in ER-negative (31 studies, SMD 0.66, 0.56–0.77, P < 0.0001), PR-negative (30 studies, SMD 0.56; 0.40–0.71, P < 0.0001), HER2-positive (32 studies, SMD − 0.29, − 0.49 to − 0.10, P = 0.0043) or Ki-67-positive (19 studies, SMD − 0.77; − 0.93 to − 0.61, P < 0.0001) primary tumours compared to their counterparts. The majority of clinical subtypes were either luminal A (LA), luminal B (LB), HER2-positive or triple negative breast cancer (TNBC). LA is associated with significantly lower SUVmax compared to LB (11 studies, SMD − 0.49, − 0.68 to − 0.31, P = 0.0001), HER2-positive (15 studies, SMD − 0.91, − 1.21 to − 0.61, P < 0.0001) and TNBC (17 studies, SMD − 1.21, − 1.57 to − 0.85, P < 0.0001); and LB showed significantly lower uptake compared to TNBC (10 studies, SMD − 0.77, − 1.05 to − 0.49, P = 0.0002). Differences in SUVmax between LB and HER2-positive (9 studies, SMD − 0.32, − 0.88 to 0.24, P = 0.2244), and HER2-positive and TNBC (17 studies, SMD − 0.29, − 0.61 to 0.02, P = 0.0667) are not significant. Conclusion Primary tumour SUVmax is significantly higher in ER-negative, PR-negative, HER2-positive and Ki-67-positive breast cancer patients. Luminal tumours have the lowest and TNBC tumours the highest SUVmax. HER2 overexpression has an intermediate effect.

show abstract

Gallium-68-Labelled Fibroblast Activation Protein Inhibitor PET/CT in the clinical diagnosis and management of breast cancer: Comparison with [18F]FDG PET/CT

Guo

Fan

et al. 2022

Preprint

View full text Add to dashboard Cite

Purpose To evaluate the diagnostic accuracy and clinical impact of gallium-68-labelled fibroblast activation protein inhibitor ([68Ga]Ga-FAPI) PET/CT in primary and metastatic breast cancer and compare the results with those of standard-of-care imaging (SCI) and [18F]Fluorodeoxyglucose (FDG) PET/CT. Methods Patients with diagnosed or suspected breast cancer who underwent concomitant [68Ga] Ga-FAPI (FAPI-46) and [18F]FDG PET/CT scans from October 2019 to March 2022 were retrospectively analysed. Breast ultrasound (US) imaging was performed in all treatment-naïve patients as SCI. The maximum standard uptake value (SUVmax), tumour-to-background ratio (TBR), lesion detection rate, and tumour-node-metastasis (TNM) classifications between [68Ga]Ga-FAPI and [18F]FDG PET/CT were evaluated, and compared. Results Twenty-eight women (median age, 52.5 y; range, 28–80 y) were included. Among them, 5 patients underwent evaluation for a definitive diagnosis of suspected breast lesions, 9 underwent initial staging, and 14 were evaluated for the detection of recurrence. The sensitivities of breast US, [18F]FDG, and [68Ga]Ga-FAPI PET/CT for detecting primary breast tumours were 80%, 70%, and 100%, respectively. Regarding the diagnosis of recurrent/metastatic lesions, the per-lesion detection rate of [68Ga]Ga- FAPI PET/CT was significantly higher than that of [18F]FDG, which including local and regional recurrence (128 vs. 88), neck lymph node (LN) metastases (33 vs. 15), abdomen LN metastases (28 vs. 3), bone metastases (146 vs. 59), and liver metastases (28 vs. 11). Compared with [18F]FDG, [68Ga]Ga-FAPI PET/CT upstaged five patients’ TNM staging/re-staging (7/27, 26%) and changed five patients’ clinical management (5/27, 19%). Compared to SCI, [68Ga]Ga-FAPI upstaged ten patients' TNM staging/re-staging (9/27, 33%) and changed the therapeutic regimen of seven patients (7/27, 26%). There was no significant association between FAPI-derived SUVmax and receptor status/histologic type in both primary and metastatic lesions. Conclusion [68Ga]Ga-FAPI PET/CT was superior to [18F]FDG in diagnosing primary and metastatic breast cancer, with higher radiotracer uptake and TBR, especially in the detection of primary/recurrent tumour, abdominal LN metastases, liver, and bone metastases. [68Ga]Ga-FAPI PET/CT is superior to [18F]FDG and SCI in TNM staging and may improve tumour staging, recurrence detection, and implementation of necessary treatment modifications.

show abstract

Asociación de características de textura de la PET/TC con [18F]FDG con las características inmunohistoquímicas en el cáncer de mama ductal infiltrante

Cited by 3 publications

References 25 publications

Predictores radiómicos F18-FDG PET/CT en la respuesta patológica completa a la quimioterapia neoadyuvante en pacientes con cáncer de mama

Predictores radiómicos F18-FDG PET/CT en la respuesta patológica completa a la quimioterapia neoadyuvante en pacientes con cáncer de mama

The influence of receptor expression and clinical subtypes on baseline [18F]FDG uptake in breast cancer: systematic review and meta-analysis

Gallium-68-Labelled Fibroblast Activation Protein Inhibitor PET/CT in the clinical diagnosis and management of breast cancer: Comparison with [18F]FDG PET/CT

Contact Info

Product

Resources

About